Theravance Biopharma, Inc. (TBPH) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 104.31M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $104.31M | (m) | (m) |
| 2026-03-31 | (m) | $109.78M | (m) | (m) |
| 2025-12-31 | (m) | $107.46M | (m) | (m) |
| 2025-09-30 | (m) | $80.33M | (m) | (m) |
| 2025-06-30 | (m) | $77.20M | (m) | (m) |
| 2025-03-31 | (m) | $65.27M | (m) | (m) |
| 2024-12-31 | (m) | $64.38M | (m) | (m) |
| 2024-09-30 | (m) | $63.19M | (m) | (m) |
| 2024-06-30 | (m) | $62.02M | (m) | (m) |
| 2024-03-31 | (m) | $61.51M | (m) | (m) |
| 2023-12-31 | (m) | $57.42M | (m) | (m) |
| 2023-09-30 | (m) | $54.51M | (m) | (m) |
| 2023-06-30 | (m) | $51.27M | (m) | (m) |
| 2023-03-31 | (m) | $48.57M | (m) | (m) |
| 2022-12-31 | (m) | $51.35M | (m) | (m) |
| 2022-09-30 | (m) | $51.64M | (m) | (m) |
| 2022-06-30 | (m) | $52.39M | (m) | (m) |
| 2022-03-31 | (m) | $54.25M | (m) | (m) |
| 2021-12-31 | (m) | $55.31M | (m) | (m) |
| 2021-09-30 | (m) | $59.09M | (m) | (m) |
| 2021-06-30 | (m) | $64.16M | (m) | (m) |
| 2021-03-31 | (m) | $66.25M | (m) | (m) |
| 2020-12-31 | (m) | $71.86M | (m) | (m) |
| 2020-09-30 | (m) | $82.63M | (m) | (m) |
| 2020-06-30 | (m) | $76.80M | (m) | (m) |
| 2020-03-31 | (m) | $87.94M | (m) | (m) |
| 2019-12-31 | (m) | $73.41M | (m) | (m) |
| 2019-09-30 | (m) | $59.65M | (m) | (m) |
| 2019-06-30 | (m) | $60.06M | (m) | (m) |
| 2019-03-31 | (m) | $57.39M | (m) | (m) |
| 2018-12-31 | (m) | $60.37M | (m) | (m) |
| 2018-09-30 | (m) | $49.15M | (m) | (m) |
| 2018-06-30 | (m) | $40.59M | (m) | (m) |
| 2018-03-31 | (m) | $20.62M | (m) | (m) |
| 2017-12-31 | (m) | $15.39M | (m) | (m) |
| 2017-09-30 | (m) | $16.56M | (m) | (m) |
| 2017-06-30 | (m) | $31.36M | (m) | (m) |
| 2017-03-31 | (m) | $33.33M | (m) | (m) |
| 2016-12-31 | (m) | $48.65M | (m) | (m) |
| 2016-09-30 | (m) | $46.85M | (m) | (m) |
| 2016-06-30 | (m) | $38.47M | (m) | (m) |
| 2016-03-31 | (m) | $40.13M | (m) | (m) |
| 2015-12-31 | (m) | $42.13M | (m) | (m) |
| 2015-09-30 | (m) | $39.67M | (m) | (m) |
| 2015-06-30 | (m) | $35.30M | (m) | (m) |
| 2015-03-31 | (m) | $31.14M | (m) | (m) |
| 2014-12-31 | (m) | $11.69M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $226.00K | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $130.15M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |